In June of 2024, the United States (US) Food and Drug Administration (FDA) approved Cepheid’s GeneXpert (XpertⓇHCV) for Point of Care (POC) hepatitis C (HCV) diagnostic testing, the first of its kind for HCV in the US. The test is CLIA (Clinical Laboratory Improvement Amendment) waived, meaning the instrument is simple to use and with […]
19
Aug
Aug
This blog post contains edited excerpts from a press release originally published by the CUNY Graduate School of Public Health & Health Policy. A pioneering study sheds new light on the hepatitis C (HCV) virus epidemic among young people who inject drugs in New York City. This research, led by Drs. Honoria Guarino and Pedro […]
29
Jul
Jul
In 2022, the hepatitis C (HCV) infection rate among 18–40 year-olds in New York State (NYS) was 4.0 per 100,000 population, a 27% decrease from 5.5 new HCV infections per 100,000 in 2020. These data are now available as interactive visualizations along with HCV diagnoses and treatment/clearance data on the HCV Dashboard. Users can explore […]
06
Jun
Jun
On May 15, 2024, New York State hosted the second Annual Hepatitis C Elimination Progress Report virtual meeting to share progress toward reaching its elimination goals, as outlined in the 2021 release of the New York State Hepatitis C Elimination Plan. All of the materials and presentations from the May meeting are now available: Hepatitis […]
Announcements
Newly Released 2022 New York State Hepatitis C Elimination Metrics Data is Now Available
15
May
May
In 2022 there were 5,169 people newly diagnosed with hepatitis C (HCV) in New York State (NYS), a 9% decrease from 2021, continuing the downward trend of HCV diagnoses over the previous decade. Between 2010 and 2022, 194,375 New Yorkers were diagnosed with HCV, and of those, 53% are known to have cleared their infection […]
15
Feb
Feb
NYS Test4HepC Campaign to Promote Hepatitis C Screening During Pregnancy Universal hepatitis C screening among pregnant people was identified in the New York State Hepatitis C Elimination Plan as a priority for moving the state towards hepatitis C elimination by 2030. Effective May 3, 2024, New York State’s hepatitis C testing legislation will require all […]
Announcements
Increasing Capacity to Provide Hepatitis C Virus (HCV) Testing in Substance Use Disorder Treatment Programs
19
Jan
Jan
What is the Learning Collaborative? The New York State Hepatitis C Learning Collaborative for Substance Use Disorder Treatment Programs is a two-year initiative to help programs build capacity to provide onsite HCV testing and linkage to care. The New York State Department of Health (NYSDOH) launched the first cycle of the learning collaborative on April […]